Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Down 7.1% – Time to Sell?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) shares traded down 7.1% during trading on Friday . The company traded as low as $14.45 and last traded at $14.45. 256 shares traded hands during trading, a decline of 40% from the average daily volume of 429 shares. The stock had previously closed at $15.56.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Strong Buy”.

Ono Pharmaceutical Stock Up 0.4%

The company has a market capitalization of $6.79 billion, a P/E ratio of 14.60 and a beta of 0.34. The company has a 50 day simple moving average of $14.42 and a two-hundred day simple moving average of $14.70. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.